Overview of Stem Cell Therapy
For the past twenty-five years, researchers have made ambitious claims about stem cells potentially transforming healthcare. These exceptional cells, initially extracted from human embryos in the late 1990s, possess an incredible capacity: they can, in theory, evolve into any type of tissue within the human body. The idea was captivating—envision having spare parts ready for anything that might malfunction in your body. Nevertheless, the path from scientific promise to real-world application turned out to be significantly more complex than expected.
The field endured numerous years of exaggeration, letdowns, and even abuse from unethical clinics. Yet now, after years of meticulous research, stem cell therapy is finally beginning to fulfill its groundbreaking promise. Two pioneering treatments for epilepsy and type 1 diabetes are yielding astonishing outcomes that are transforming the lives of patients.
The Mechanism Behind Stem Cell Therapy
Stem cell therapy utilizes the inherent potential of these adaptable cells to form specialized tissues. Researchers employ either embryonic stem cells or iPSCs (adult cells that have been genetically modified to act like embryonic cells). By creating carefully managed laboratory conditions, they steer these stem cells to develop into specific cell types required for therapeutic purposes.
In the case of epilepsy treatment, stem cells become specialized neurons that generate GABA, a neurotransmitter that helps to stabilize overactive brain activity. For treating diabetes, stem cells differentiate into beta islet cells—the insulin-producing cells typically found in the pancreas that are destroyed in individuals with type 1 diabetes.
Once produced, these lab-created cells are implanted into patients. The transplanted cells integrate into existing tissues and start fulfilling their designated roles. The aim is to achieve a “functional cure,” where the patient’s body can self-regulate without the need for continuous medical assistance.
Groundbreaking Epilepsy Treatment: The Journey of Justin Graves
Justin Graves was operating a scuba diving shop in Louisville, Kentucky, when epilepsy abruptly changed the course of his life. At the age of 22, he received a diagnosis of temporal lobe epilepsy. The illness took everything—federal laws disallow anyone with a history of seizures from scuba diving, effectively ending his profession. Unable to drive, he had to move and accept any jobs he could discover along public transport routes.
By 2023, at 39 years old and two-and-a-half years sober, Graves was experiencing one to two seizures daily. When his doctors at UC San Diego proposed an experimental stem cell treatment, he readily consented. The treatment, named NRTX-1001 and developed by Neurona Therapeutics, involved the injection of thousands of lab-engineered neurons directly into his brain.
In July 2023, neurosurgeon Dr. Sharona Ben-Haim inserted a ceramic needle into his hippocampus and delivered thousands of inhibitory interneurons cultivated from stem cells. These specific cells produce GABA, potentially reducing the electrical disturbances that trigger epileptic seizures.
The outcomes surpassed expectations. Within weeks, Graves noticed a significant reduction in his seizures. By early 2025, he was having seizures only about once a week, in contrast to daily occurrences prior to treatment. Other patients shared similar positive results—one woman in Oregon remained seizure-free for eight straight months. Among the first five volunteers treated, four reported an impressive decline in seizure frequency of eighty percent or more. Additionally, patients exhibited enhancements in cognitive function, especially in memory.
For Dr. Ben-Haim, this signifies a potential shift in treatment philosophy. Conventional surgical methods typically involve removing or destroying troublesome brain tissues, carrying significant risks like memory loss and visual impairments. Providing a definitive treatment without damaging brain tissue could transform the approach to managing epilepsy.
Innovative Diabetes Treatment: Achieving a Functional Cure
Type 1 diabetes is an autoimmune disorder wherein the body annihilates insulin-producing beta cells in the pancreas. Without these cells, patients are unable to regulate blood sugar levels and must depend on constant monitoring and multiple daily insulin injections just to survive.
In June 2024, Vertex Pharmaceuticals released astonishing news. Twelve individuals with type 1 diabetes who underwent an experimental stem cell therapy known as VX-880 (later renamed zimislecel) were able to produce sufficient insulin to maintain stable blood glucose levels ninety days post a single treatment. Most impressively, three patients who were followed for an entire year no longer required any insulin injections whatsoever.
This therapy involves the differentiation of stem cells into functional beta islet cells, subsequently administered through a one-time infusion. All twelve patients who received the complete dosage achieved recommended blood sugar targets and sustained healthy glucose levels. Their bodies achieved self-regulation in a manner they hadn’t been capable of since their diagnosis.
This represents a “functional cure.” While patients need to take immunosuppressive medications to avert rejection and require ongoing monitoring, for many, the change has been life-altering.